Intraperitoneal chemotherapy for peritoneal metastases using sustained release formula of cisplatin-incorporated gelatin hydrogel granules

  • Kota Yamashita
  • Shigeru TsunodaEmail author
  • Shutaro Gunji
  • Takahide Murakami
  • Takahisa Suzuki
  • Yasuhiko Tabata
  • Yoshiharu Sakai
Original Article



We previously reported the effectiveness of gelatin microspheres incorporating cisplatin in a mouse model of peritoneal metastases. In this study, we report our new complete sustained-release formula of gelatin hydrogel granules incorporating cisplatin (GHG–CDDP), which exerted a good anti-tumor effect with less toxicity.


GHG–CDDP was prepared without organic solvents to enable its future clinical use. The pharmaceutical characterization of GHG–CDDP was performed, and its in vivo degradability was evaluated. The anti-tumor effect was evaluated using a murine peritoneal metastasis model of the human gastric cancer MKN45-Luc cell line.


Our new manufacturing process dramatically reduced the initial burst of CDDP release to approximately 2% (wt), while the previous product had a 25–30% initial burst. In intraperitoneal degradation tests, approximately 30% of GHG–CDDP remained in the murine abdominal cavity 7 days after intraperitoneal injection and disappeared within 3 weeks. GHG–CDDP significantly suppressed the in vivo tumor growth (p = 0.02) and prolonged the survival time (p = 0.0012) compared with the control. In contrast, free CDDP did not show a significant therapeutic effect at any dose. Weight loss and hematological toxicity were also significantly ameliorated.


GHG–CDDP is a promising treatment option for peritoneal metastases through the complete sustained-release of CDDP with less systemic toxicity.


Gelatin hydrogel Peritoneal metastases Intraperitoneal chemotherapy Cisplatin Gastric cancer 



The authors would like to thank Dr. Takaki Sakurai for providing veterinary pathology opinions. This work was supported in part by a JSPS Grant-in-Aid for Scientific Research (C) Grant number JP15K08586.

Author contributions

KY, ST, YT, and YS designed the studies. KY, TM, and TS performed the experiments. KY and ST conducted the experiments and analyzed the data. SG assisted with the design of the experiments. KY and ST wrote the manuscript. YT and YS supervised and edited the manuscript. All authors contributed to the research.

Compliance with ethical standards

Conflict of interest

The authors confirm that they have no conflict of interest.


  1. 1.
    Sugarbaker PH. Peritoneal metastases from gastrointestinal cancer. Curr Oncol Rep 2018;20:62CrossRefPubMedGoogle Scholar
  2. 2.
    Huo YR, Richards A, Liauw W Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol 2015;41:1578–1589.CrossRefPubMedGoogle Scholar
  3. 3.
    Yan TD, Black D, Savady R. Sugarbaker PH Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006;24:4011–4019.CrossRefPubMedGoogle Scholar
  4. 4.
    Esquivel J. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: Survival outcomes and patient selection. J Gastrointest Oncol 2016;7:72–78.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 2015;22:1686–1693.CrossRefPubMedGoogle Scholar
  6. 6.
    Elias D, Goéré D, Dumont F, Honoré C, Dartigues P, et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer 2014;50:332–340.CrossRefPubMedGoogle Scholar
  7. 7.
    Alexander HR, Li CY, Kennedy TJ. Current management and future opportunities for peritoneal metastases: peritoneal mesothelioma. Ann Surg Oncol 2018;25:2159–2164.CrossRefPubMedGoogle Scholar
  8. 8.
    Choudry HA, Pai RK. Management of mucinous appendiceal tumors. Ann Surg Oncol 2018;25:2135–2144.CrossRefPubMedGoogle Scholar
  9. 9.
    Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 2010;36:456–462.CrossRefPubMedGoogle Scholar
  10. 10.
    Baratti D, Kusamura S, Pietrantonio F, Guaglio M, Niger M, et al. Progress in treatments for colorectal cancer peritoneal metastases during the years 2010–2015. A systematic review. Crit Rev Oncol Hematol 2016;100:209–222.CrossRefPubMedGoogle Scholar
  11. 11.
    Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: progress toward a new standard of care. Cancer Treat Rev 2016;48:42–49.CrossRefPubMedGoogle Scholar
  12. 12.
    Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 1998;9:13–21.CrossRefPubMedGoogle Scholar
  13. 13.
    Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.CrossRefPubMedGoogle Scholar
  14. 14.
    Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994;12:970–974.CrossRefPubMedGoogle Scholar
  15. 15.
    Miyashiro I, Furukawa H, Sasako M, Yamamoto S, Nashimoto A, et al. Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2. Gastric Cancer 2011;14:212–218.CrossRefPubMedGoogle Scholar
  16. 16.
    Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751–60.CrossRefPubMedGoogle Scholar
  17. 17.
    Yokoyama M, Okano T, Sakurai Y, Suwa S, Kataoka K. Introduction of cisplatin into polymeric micelle. J Controll Release 1996;39:351–356.CrossRefGoogle Scholar
  18. 18.
    Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 2005;93:678–687.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Iinuma H, Maruyama K, Okinaga K, Sasaki K, Sekine T, et al. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer 2002;99:130–137.CrossRefPubMedGoogle Scholar
  20. 20.
    Gunji S, Obama K, Matsui M, Tabata Y, Sakai Y. A novel drug delivery system of intraperitoneal chemotherapy for peritoneal carcinomatosis using gelatin microspheres incorporating cisplatin. Surgery 2013;154:991–999.CrossRefPubMedGoogle Scholar
  21. 21.
    Matsui M, Tabata Y. Enhanced angiogenesis by multiple release of platelet-rich plasma contents and basic fibroblast growth factor from gelatin hydrogels. Acta Biomater 2012;8:1792–1801.CrossRefPubMedGoogle Scholar
  22. 22.
    Ahmed T, Review. Approaches to develop PLGA based in situ gelling system with low initial burst. Pak J Pharm Sci 2015;28:657–665.PubMedGoogle Scholar
  23. 23.
    Yeo Y, Park K. Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch Pharmacal Res 2004;27:1–12.CrossRefGoogle Scholar
  24. 24.
    Nguyen MH, Tran TT, Hadinoto K. Controlling the burst release of amorphous drug-polysaccharide nanoparticle complex via crosslinking of the polysaccharide chains. Eur J Pharm Biopharm 2016;104:156–163.CrossRefPubMedGoogle Scholar
  25. 25.
    Young S, Wong M, Tabata Y, Mikos AG. Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J Control Release 2005;109:256–274.CrossRefPubMedGoogle Scholar
  26. 26.
    Tabata Y, Ikada Y. Vascularization effect of basic fibroblast growth factor released from gelatin hydrogels with different biodegradabilities. Biomaterials. 1999;20:2169–75.CrossRefPubMedGoogle Scholar
  27. 27.
    Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v38CrossRefPubMedGoogle Scholar
  28. 28.
    Markman M, Intraperitoneal chemotherapy. Crit Rev Oncol Hematol. 1999;31:239–46.CrossRefPubMedGoogle Scholar
  29. 29.
    Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 2003;4:277–283.CrossRefPubMedGoogle Scholar
  30. 30.
    Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34–43.CrossRefPubMedGoogle Scholar
  31. 31.
    Okabe H, Ueda S, Obama K, Hosogi H, Sakai Y. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol 2009;16:3227–3236.CrossRefPubMedGoogle Scholar
  32. 32.
    Satoh S, Hasegawa S, Ozaki N, Okabe H, Watanabe G, et al. Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination. Gastric Cancer. 2006;9:129–35.CrossRefPubMedGoogle Scholar
  33. 33.
    Satoh S, Okabe H, Teramukai S, Hasegawa S, Ozaki N, et al. Phase II trial of combined treatment consisting of preoperative S-1 plus cisplatin followed by gastrectomy and postoperative S-1 for stage IV gastric cancer. Gastric Cancer 2012;15:61–69.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Surgery, Graduate School of MedicineKyoto UniversityKyotoJapan
  2. 2.Department of Biomaterials, Field of Tissue Engineering, Institute for Frontier Life and Medical SciencesKyoto UniversityKyotoJapan

Personalised recommendations